Retrospective cohort study demonstrated significant reduction
in medical costs for Dario users with Type 2 diabetes compared to
non-users driven by a significant reduction in in-patient
hospitalizations after one year
NEW
YORK, July 26, 2023 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced today a new analysis by
Sanofi US demonstrating a significant reduction in the cost of care
for Dario users compared to non-users living with Type 2 diabetes.
The study used matched claims to show an estimated $5,077 in medical cost savings for Dario users
compared to non-users.
Study Ties Significant Cost Reductions to Lower Healthcare
Utilization for Dario Users
The new research data, presented by Sanofi at the American
Diabetes Association 83rd Scientific Sessions (the
"Scientific Sessions"), examined associated claims for Dario users
and non-users to determine the potential savings for patients
living with Type 2 diabetes.
The study used an exact match and propensity-score matched
non-user cohort that included access to usual care in a cohort of
2,445 Dario users and 7,334 matched non-users. Cost-to-charge
ratios were used to determine potential paid savings in costs of
care across both inpatient and outpatient care. The study found
Dario users incurred a total of $5,077 less in estimated payer charges over the
course of a year compared to non-Dario users.
"Digital health historically lacks the rigorous research needed
to help payers assess value, and our partners at Sanofi are
charting a new standard with this robust, arms-length analysis of
Dario user data," said Omar
Manejwala, M.D., Chief Medical Officer of Dario. "We are
incredibly proud to share this new data resulting from a rigorous
well matched study design to offer the credible evidence of cost
savings our partners demand."
"Our studies have shown not only the effectiveness and safety of
a digital health intervention, but also how this can save spending
for health systems," said Felix Lee,
Medical Head of Digital Healthcare, Sanofi US. "Digital health has
the potential to address gaps in chronic care in addition to usual
pharmaceutical care to improve clinical and economic outcomes and
we are excited to be innovating in how best to showcase these
benefits."
Dario and Sanofi Research: Setting New Standards for
Evidence-Based Digital Health
This research study, conducted by Sanofi, is part of Dario and
Sanofi's ground-breaking collaboration to set new standards in
digital health research by analyzing real-world digital health data
using the evidence generation principles of a pharmaceutical study.
To read more about this research, click here.
The analysis used HIPAA-complaint deidentified patient data
linking claims data to construct the study cohorts. All data in
these studies was collected following receipt of all required
patient consents.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Our platform and suite of solutions
deliver personalized and dynamic interventions driven by data
analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Our user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the potential benefits and costs savings realized by the use of its
products, and the potential benefits of digital health
intervention. Without limiting the generality of the foregoing,
words such as "plan," "project," "potential," "seek," "may,"
"will," "expect," "believe," "anticipate," "intend," "could,"
"estimate" or "continue" are intended to identify forward-looking
statements. Readers are cautioned that certain important factors
may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements
that may be made in this news release. Factors that may affect the
Company's results include, but are not limited to, regulatory
approvals, product demand, market acceptance, impact of competitive
products and prices, product development, commercialization or
technological difficulties, the success or failure of negotiations
and trade, legal, social and economic risks, and the risks
associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the
Company's actual results and forward-looking statements include,
but are not limited to, those risks discussed in the Company's
filings with the U.S. Securities and Exchange Commission. Readers
are cautioned that actual results (including, without limitation,
the timing for and results of the Company's commercial and
regulatory plans for Dario™ as described herein) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
Media Contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
View original
content:https://www.prnewswire.com/news-releases/new-research-shows-5-077-in-medical-costs-savings-for-dario-users-301886177.html
SOURCE DarioHealth Corp.